Evidence map›Paper›PMID 36876026›Full record

ArticleToxicology reports2023

Chemical and

Tsuneo Hashizume, Shinkichi Ishikawa, Kazushi Matsumura, Shigeaki Ito, Toshiro Fukushima

Abstract read
In one paragraph

Article in Toxicology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tsuneo HashizumeScientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Yokohama, 6-2 Umegaoka, Aoba-ku, Kanagawa 227-8512, Japan.
Shinkichi IshikawaScientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Yokohama, 6-2 Umegaoka, Aoba-ku, Kanagawa 227-8512, Japan.
Kazushi MatsumuraScientific and Regulatory Affairs, JT International SA, 8 rue Kazem Radjavi, 1202 Geneva, Switzerland.
Shigeaki ItoScientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Yokohama, 6-2 Umegaoka, Aoba-ku, Kanagawa 227-8512, Japan.
Toshiro FukushimaScientific Product Assessment Center, R&D Group, Japan Tobacco Inc., Yokohama, 6-2 Umegaoka, Aoba-ku, Kanagawa 227-8512, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has previously been found that, compared with cigarette smoke, the aerosols generated by heated tobacco products contain fewer and lower harmful and potentially harmful constituents (HPHCs) and elicit lower biological activity in

Indexed as

ACM, aerosol collected massAqE, aqueous extractARE, anti-oxidant responsive elementBDL, below detection limitCMF-PBS, calcium- and magnesium-free phosphate buffered salineCS, cigarette smokeCytotoxicityDT3.0a, Direct Heating Tobacco System Platform 3 generation 3 version aGenotoxicityGFP, green fluorescent proteinGVP, gas-vapor phaseHeated tobacco productHPHCsHPHCs, harmful and potentially harmful constituentsHTP, heated tobacco productIC50, half maximal inhibitory concentrationIn vitroISO, International Organization for StandardizationLOD, limit of detectionLOQ, limit of quantificationmES, mouse embryonic stemMLA, mouse lymphoma assayMN, micronucleusMRTP, modified risk tobacco productNQ, not quantifiedNRU, neutral red uptakeOxidative stressROS, reactive oxygen speciesTHP, tobacco heating productTHS, tobacco heating systemTPM, total particulate matter

Identifiers

PMID36876026
PMCPMC9976195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.